{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:29:45Z","timestamp":1789223385284,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":227,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109214","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:50:23Z","timestamp":1660387823000},"page":"109214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines"],"prefix":"10.1016","volume":"219","author":[{"given":"Sean J.","family":"Belouin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette A.","family":"Averill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Xenakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Magar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia L.","family":"Danforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109214_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109214_bib2","series-title":"FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials","author":"Assocation of Psychedelic Studies","year":"2017"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109214_bib3","first-page":"103","article-title":"FDA intensifies drive to reduce REMS burdens: the key objective is to ease workflow obstacles for pharmacists","volume":"41","author":"Barlas","year":"2016","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1016\/j.neuropharm.2022.109214_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109214_bib5","first-page":"1","article-title":"Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","author":"Bender","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109214_bib6","author":"Board of Chaplaincy Certification Inc"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109214_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamapsychiatry.2022.0665","article-title":"Toward risk-benefit assessments in psychedelic-and MDMA-assisted therapies","volume":"79","author":"Bradberry","year":"2022","journal-title":"JAMA Psychiatr."},{"issue":"15","key":"10.1016\/j.neuropharm.2022.109214_bib8","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109214_bib9","series-title":"COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-Resistant Depression","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109214_bib10","series-title":"Statement on Open Science and Open Praxis with Psilocybin, MDMA, and Similar Substances","year":"2021"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109214_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109214_bib12","series-title":"Policy and Legal Considerations for Religious and Community Use of Psilocybin Mushrooms under Oregon Measure 109","author":"Dennis","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109214_bib13","series-title":"Peyote and Psychedelics on the Canadian Prairies. BC Labate Y C. Cavnar, Peyote. History, Tradition, Politics and Conservation","first-page":"151","author":"Dyck","year":"2016"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109214_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/02698811211050543","article-title":"A narrative synthesis of research with 5-MeO-DMT","volume":"36","author":"Ermakova","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109214_bib14","series-title":"Oregon Becomes First State to Legalize Magic Mushrooms as More States Ease Drug Laws in \u2018psychedelic Renaissance\u2019","author":"Feuer","year":"2020"},{"key":"10.1016\/j.neuropharm.2022.109214_bib15","series-title":"Flesh of the Gods","author":"Furst","year":"1972"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109214_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acsptsci.0c00171","article-title":"Ethical concerns about psilocybin intellectual property","volume":"4","author":"Gerber","year":"2021","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.neuropharm.2022.109214_bib17","article-title":"Psychedelic therapy has a sexual abuse problem","author":"Goldhill","year":"2020","journal-title":"Quartz"},{"key":"10.1016\/j.neuropharm.2022.109214_bib18","series-title":"Cannabis in the Provinces and Territories","author":"Government of Canada","year":"2022"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109214_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109214_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","article-title":"Human psychopharmacology of hoasca, A plant hallucinogen used in ritual context in Brazil","volume":"184","author":"Grob","year":"1996","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109214_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/1751696X.2014.993244","article-title":"Psychoactive substances in prehistoric times: examining the archaeological evidence","volume":"8","author":"Guerra-Doce","year":"2015","journal-title":"Time Mind"},{"key":"10.1016\/j.neuropharm.2022.109214_bib22","series-title":"LSD: My Problem Child","author":"Hofmann","year":"2013"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109214_bib23","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","article-title":"Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","volume":"237","author":"Jerome","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109214_bib24","series-title":"Johns Hopkins Medicine Receives First Federal Grant for Psychedelic Treatment Research in 50 Years","year":"2021"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109214_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109214_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109214_bib27","series-title":"Usona Institute's Psilocybin Receives the US FDA Breakthrough Therapy Designation for Major Depressive Disorder","author":"Khan","year":"2019"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109214_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugpo.2011.06.006","article-title":"Ayahuasca and the process of regulation in Brazil and internationally: implications and challenges","volume":"23","author":"Labate","year":"2012","journal-title":"Int. J. Drug Pol."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109214_bib29","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0269881118793086","article-title":"Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016","volume":"32","author":"Leonard","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109214_bib30","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1445-5994.2012.02955.x","article-title":"A fatal case of'magic mushroom'ingestion in a heart transplant recipient","volume":"42","author":"Lim","year":"2012","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.neuropharm.2022.109214_bib31","author":"Love"},{"key":"10.1016\/j.neuropharm.2022.109214_bib32","first-page":"1","article-title":"Serotonin toxicity of serotonergic psychedelics","author":"Malcolm","year":"2021","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109214_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239997","article-title":"The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD","volume":"15","author":"Marseille","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109214_bib34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109214_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109214_bib36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"Nichols","year":"2016","journal-title":"Psychedelics. Pharmacological Reviews"},{"key":"10.1016\/j.neuropharm.2022.109214_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109214_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjsit-2019-000003","article-title":"Determining value of coordinated registry networks (CRNs): a case of transcatheter valve therapies","volume":"1","author":"Pappas","year":"2019","journal-title":"BMJ Surgery, Interventions, & Health Technologies"},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109214_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0022167817711304","article-title":"Developing guidelines and competencies for the training of psychedelic therapists","volume":"57","author":"Phelps","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109214_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamapsychiatry.2021.3972","article-title":"The rapid rise in investment in psychedelics\u2014cart before the horse","volume":"79","author":"Phelps","year":"2022","journal-title":"JAMA Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109214_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-021-00489-1","article-title":"Ethical and legal issues in psychedelic harm reduction and integration therapy","volume":"18","author":"Pilecki","year":"2021","journal-title":"Harm Reduct. J."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109214_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109214_bib43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109214_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.05.019","article-title":"Registered clinical studies investigating psychedelic drugs for psychiatric disorders","volume":"139","author":"Siegel","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109214_bib45","doi-asserted-by":"crossref","first-page":"e210001","DOI":"10.1001\/jamahealthforum.2021.0001","article-title":"CDC warns of surge in drug overdose deaths during COVID-19","volume":"2","author":"Stephenson","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.neuropharm.2022.109214_bib46","series-title":"National Survey on Drug Use and Health (NSDUH)","author":"Substance Abuse and Mental Health Services Administration","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109214_bib47","series-title":"Convention on Psychotropic Substances","author":"United Nations","year":"1971"},{"key":"10.1016\/j.neuropharm.2022.109214_bib48","series-title":"21 U.S. Code \u00a7 355\u20131 - Risk Evaluation and Mitigation Strategies","author":"United States Code","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109214_bib49","series-title":"Diversion Control Division","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109214_bib50","series-title":"Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry","author":"US Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.neuropharm.2022.109214_bib51","series-title":"Expanded Access to Investigational Drugs for Treatment Use \u2014Questions and Answers. Guidance for Industry","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2022.109214_bib52","series-title":"Breakthrough Therapy","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.neuropharm.2022.109214_bib53","series-title":"Risk Evaluation and Mitigation Strategies | REMS","author":"US Food and Drug Administration","year":"2021"},{"issue":"10185","key":"10.1016\/j.neuropharm.2022.109214_bib54","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(19)31082-7","article-title":"Denver votes to decriminalise psilocybin mushrooms","volume":"393","author":"Webster","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109214_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116820","article-title":"The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010","volume":"10","author":"Whiteford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109214_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnins.2020.00078","article-title":"NBOMes\u2013highly potent and toxic alternatives of LSD","volume":"14","author":"Zawilska","year":"2020","journal-title":"Front. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:27Z","timestamp":1758439167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":57,"alternative-id":["S0028390822002738"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109214","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109214"}}